• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

An R848 adjuvanted influenza vaccine promotes early activation of B cells in the draining lymph node of nonhuman primate neonates

tetano

Editor, Senior Moderator
Immunology. 2017 Sep 22. doi: 10.1111/imm.12845. [Epub ahead of print]
[h=1]An R848 adjuvanted influenza vaccine promotes early activation of B cells in the draining lymph node of nonhuman primate neonates.[/h] Holbrook BC[SUP]1[/SUP], Aycock ST[SUP]2[/SUP], Machiele E[SUP]1[/SUP], Clemens E[SUP]1[/SUP], Gries D[SUP]1[/SUP], Jorgensen MJ[SUP]3[/SUP], Hadimani MB[SUP]4[/SUP], King SB[SUP]4[/SUP], Alexander-Miller MA[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Impaired immune responsiveness is a significant barrier to vaccination of neonates. By way of example, the low seroconversion observed following influenza vaccination has led to restriction of its use to infants over 6 months of age, leaving younger infants vulnerable to infection. Our previous studies using a nonhuman primate neonate model demonstrated that the immune response elicited following vaccination with inactivated influenza virus could be robustly increased by inclusion of the TLR agonist flagellin or R848, either delivered individually or in combination. When delivered individually, R848 was found to be the more effective of the two. To gain insights into the mechanism through which these adjuvants functioned in vivo, we assessed the initiation of the immune response, i.e. at 24h, in the draining lymph node of neonate nonhuman primates. Significant upregulation of costimulatory molecules on DCs could be detected, but only when both adjuvants were present. In contrast, R848 alone could increase the number of cells in the lymph node, presumably through enhanced recruitment, as well as B cell activation at this early timepoint. These changes were not observed with flagellin and the dual adjuvanted vaccine did not promote increases beyond those observed with R848 alone. In vitro studies showed that R848 could promote B cell activation, supporting a model wherein a direct effect on neonate B cell activation is an important component of the in vivo potency of R848 in neonates. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.


PMID: 28940186 DOI: 10.1111/imm.12845
 
Back
Top Bottom